Transparency data

Aggregate net sales and payment information: August 2021

Published 10 September 2021

Table 1: unaudited sales reports: measured sales

Aggregate net sales subject to the affordability mechanism (measured sales):

Year 2019 voluntary scheme Statutory scheme Parallel imports Total
2018 £8,847³¾ £1,654³¾ £771³¾ £11,272³¾
2019 Q1 £2,195³¾ £411³¾ £183³¾ £2,788³¾
2019 Q2 £2,178³¾ £422³¾ £170³¾ £2,770³¾
2019 Q3 £2,304³¾ £419³¾ £166³¾ £2,888³¾
2019 Q4 £2,401³¾ £423³¾ £179³¾ £3,004³¾
2019 £9,089³¾ £1,671³¾ £698³¾ £11,458³¾
2020 Q1 £2,750³¾ £99³¾ £191³¾ £3,040³¾
2020 Q2 £2,401³¾ £95³¾ £176³¾ £2,673³¾
2020 Q3 £2,617³¾ £87³¾ £199³¾ £2,903³¾
2020 Q4 £2,940³¾ £98³¾ £200³¾ £3,238³¾
2020 £10,710³¾ £379³¾ £766³¾ £11,856³¾
2021 Q1 £2,725³¾ £93³¾ £177³¾ £2,995³¾
2021 Q2 £2,818³¾ £100³¾ £192³¾ £3,110³¾

Table 1 notes

  1. Table 1 sets out aggregate information about measured sales subject to the affordability mechanism. It includes information received on parallel imports and information from audited annual sales reports and unaudited quarterly sales reports provided by members of the 2019 voluntary scheme and the statutory scheme.
  2. The baseline for measured sales in respect of the statutory scheme and parallel imports has been calculated in accordance with Annex 4, paragraph 1 of the 2019 voluntary scheme.
  3. Measured sales is defined in the glossary of the 2019 voluntary scheme for branded medicines pricing and access as “sales of scheme products by scheme members, statutory scheme sales and parallel import sales, but excluding exemptions from measured sales�.
  4. Figures for the 2019 voluntary scheme reflect any audited sales reports received. Annual totals from 2019 onwards for the statutory scheme reflect any audited sales reports received.

Measured sales in any particular period reflects all relevant scheme members in either the 2019 voluntary scheme or statutory scheme during that period. For example, several companies moved from the statutory scheme to the voluntary scheme at the start of 2020. Those companies� measured sales will appear under the statutory scheme in 2019 but the Voluntary Scheme in 2020.

Table 2: 2019 voluntary scheme sales reports: eligible sales and resulting total scheme payments

Period Aggregate eligible sales (column 1) Resulting aggregate scheme payments (column 2)
2019 £8,794³¾ £844³¾
2020 Q1 £2,546³¾ £150³¾
2020 Q2 £2,289³¾ £135³¾
2020 Q3 £2,497³¾ £147³¾
2020 Q4 £2,746³¾ £162³¾
2020 £10,080³¾ £595³¾
2021 Q1 £2,446³¾ £125³¾
2021 Q2 £2,624³¾ £134³¾

Table 2 notes

Table 2, which is derived from unaudited quarterly sales reports and any audited annual sales reports received from members of the 2019 voluntary scheme, sets out aggregate information showing eligible sales covered by the scheme payment and the resulting scheme payments.

There are 2 columns of information:

  • column 1: aggregate eligible sales
  • column 2: resulting aggregate scheme payments due for the respective periods

Note: eligible sales is defined in the glossary of the 2019 voluntary scheme as “sales of scheme products but excluding exemptions from eligible sales�. The percentage payment applies to these sales. Eligible sales excludes certain types of sales, including the first £5 million of sales by a medium-sized company and new active substance (NAS) sales. Both of these sales categories are, however, included in measured sales and, therefore, the calculation of the overall sum to be repaid across all scheme members.

Table 3: statutory scheme sales reports: net sales covered by the statutory scheme payment and resulting payments

Statutory scheme payment and resulting payments 2019 Jan to Mar 2020 Apr to Jun 2020 Jul to Sep 2020 Oct to Dec 2020 2020
Aggregate net sales covered by the applicable annual statutory scheme payment (a) £633³¾ £5³¾ £7³¾ £10³¾ £11³¾ £34³¾
Resulting aggregate statutory scheme payment (b) £63³¾ £1³¾ <£1³¾ £1³¾ £1³¾ £2³¾
Net sales of extant frameworks and public contracts subject to 7.8% payment (c) £308³¾ £4³¾ £4³¾ £4³¾ £5³¾ £17³¾
Resulting statutory scheme 7.8% payment (d) £24³¾ <£1³¾ <£1³¾ <£1³¾ <£1³¾ £1³¾
Total resulting statutory scheme payment (b + d) £87³¾ £1³¾ £1³¾ £1³¾ £1³¾ £4³¾
Statutory scheme payment and resulting payments Jan to Mar 2021 Apr to Jun 2021
Aggregate net sales covered by the applicable annual statutory scheme payment (a) £8³¾ £17³¾
Resulting aggregate statutory scheme payment (b) £1³¾ £2³¾
Net sales of extant frameworks and public contracts subject to 7.8% payment (c) £4³¾ £4³¾
Resulting statutory scheme 7.8% payment (d) <£1³¾ <£1³¾
Total resulting statutory scheme payment (b + d) £1³¾ £2³¾

Table 3 notes

Table 3 is derived from audited and unaudited statutory scheme sales reports. It sets out aggregate unaudited quarterly information showing net sales covered by the statutory scheme payment and the resulting payments.

General notes

Note 1: The information in all tables is that held on the Department of Health and Social Care’s database at 12 August 2021.

Note 2: Totals may not sum due to rounding.

Note 3: All tables are subject to future correction such as where audited data replaces best available data and will be updated at each quarterly publication point to reflect the latest available information. The audit and reconciliation arrangements are set out in paragraphs 4.26 to 4.31 of the 2019 voluntary scheme. The statutory scheme audit requirements are set out at paragraph 23 of the regulations.